Changes are being made to a prematurely published study that proposes an EU drug procurement authority, a centralized pharmaceutical fund and a European pharmaceutical R&D infrastructure to match public health needs with R&D investment.
The European Parliament’s Panel for the Future of Science and Technology (STOA) has produced a study that proposes a number of options for improving access to medicines in the EU while promoting pharmaceutical innovation, such as reductions in data and market exclusivity and new incentives to promote R&D in areas of unmet need.
The study, which was mistakenly published and is yet to be finalized, also suggests the creation of an EU drug...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
